Artikel
Bcl-2/Bcl-xL inhibition synergistically enhances the anti-neoplastic activity of CUSP9v3 against glioblastoma cells in vitro
Synergistische Verstärkung der anti-neoplastischen Aktivität von CUSP9v3 gegen Glioblastomzellen durch Hemmung von Bcl-2/Bcl-xL in vitro
Suche in Medline nach
Autoren
Veröffentlicht: | 8. Mai 2019 |
---|
Gliederung
Text
Objective: Repurposing represents a promising approach to safely accelerate the clinical application of therapeutics with anti-cancer activity. In this study, we examined whether inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL enhances the biological effects of the repurposed CUSP9v3 regimen in an in vitro setting of glioblastoma.
Methods: We applied MTT assays to assess cellular proliferation. Annexin V/PI and TMRE staining were used to examine apoptosis. Western blotting, RT-PCR and specific knockdown experiments using siRNA were employed to examine molecular mechanisms of action.
Results: Bcl-2/Bcl-xL inhibition yielded synergistic anti-proliferative effects across a wide panel of established and primary cultured glioblastoma cells when combined with CUSP9v3 which had been reduced to only one tenth of its original concentration (CUSP9v3 1/10). The combination treatment also led to enhanced apoptosis with loss of mitochondrial membrane potential and activation of caspases. On the molecular level, CUSP9v3 1/10 counteracted ABT263-mediated upregulation of Mcl-1 and led to suppression of Bcl-xL. Silencing of Mcl-1 enhanced ABT263-mediated apoptosis, indicating that Mcl-1 is crucial for the induction of cell death conveyed by the combination treatment. Levels of Mcl-1 mRNA were not decreased following combination therapy, and co-treatment with cycloheximide showed reduced protein stability, pointing towards a post-translational mechanism of action.
Conclusion: These data suggest that Bcl-2/Bcl-xL inhibition enhances the susceptibility of glioblastoma cells towards CUSP9v3, allowing dramatic dose reduction and potentially decreased toxicity when applied clinically. A clinical trial involving the original CUSPv3 doses is currently ongoing in our institution (NCT02770378). The Bcl-2/Bcl-xL inhibitor ABT263 is used in clinical trials and might represent a valuable adjunct to CUSPv3.